Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass.
We investigated the effect of daily therapy with 1 mcg alfacalcidol (Doss(®)-TEVA/AWD-pharma) on muscle power, muscle function, balance performance and fear of falls in an open, multi-centered, uncontrolled, prospective study on a cohort of patients with reduced bone mass. Among the 2,097 participants, 87.1% were post-menopausal women and 12.9% were men. Mean age was 74.8 years and mean body mass index (BMI) 26.3 kg/m². A total of 75.3% of the study population had osteoporosis, 81% a diagnosis of "increased risk of falls" and 70.1% had a creatinine clearance (CrCl) of <65 ml/min. Participants underwent muscle function and muscle power tests at onset and after 3 and 6 months: the timed up and go test (TUG) and the chair rising test (CRT). At baseline and after 6 months, participants performed the tandem gait test (TGT) and filled out a questionnaire evaluating fear of falling. Successful performance in the muscle tests is associated with a significantly lower risk of falls and non-vertebral fractures in elderly patients (successful test performance: TUG ≤ 10 s (sec), CRT ≤ 10 s, TGT ≥ 8 steps). A significant improvement in the performance of the two muscle tests was proved already after 3 months of treatment with alfacalcidol and further increased by the end of the therapeutic intervention. There were significant increases in the number of participants able to successfully perform the tests: 24.6% at baseline and 46.3% at the end of trial for the TUG (P < 0.0001) and 21.7% at baseline and 44.2% at the end for the CRT test (P = 0.0001). The mean time used for the TUG was decreased by 3.0 s from the average onset value of 17.0 s and by 3.1 s from the initial average 16.5 s for the CRT. The percentage of participants able to perform the balance test (TGT) increased from 36.0% at onset to 58.6% at the end of the trial (P < 0.0001). An increased fear of falling was reduced by the end of the study in 74.4% of the patients. Throughout the study, there were 26 adverse drug reactions in 11 out of 2,097 patients (incidence 0.52%). No serious adverse drug reactions and no cases of hypercalcemia were documented. We conclude that treatment with alfacalcidol is safe, increases muscle power, muscle function and balance and reduces fear of falls. The significant improvement in the three muscle and balance tests and fear of falls may have a preventative effect on falls and fractures. We suggest that the quantitative risk tests used in this study could be reliable surrogate parameters for the risk of falls and fractures in elderly patients.
Schacht
E
E
ZORG (Zurich Osteoporosis Research Group), Zollikerberg, Switzerland.
Ringe
Johann D
JD
D000058:Accidental Falls / Q000517:prevention & control; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005239:Fear / Q000523:psychology; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D053580:Muscle Strength / Q000187:drug effects* / Q000502:physiology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D004856:Postural Balance / Q000187:drug effects* / Q000502:physiology; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; C008088:alfacalcidol
J Am Geriatr Soc. 1995 Jun;43(6):603-9
7775716
J Am Geriatr Soc. 2001 May;49(5):664-72
11380764
Stroke. 1997 Apr;28(4):736-9
9099188
Rheumatol Int. 2009 Aug;29(10):1177-85
19159932
J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84
16172518
J Gerontol A Biol Sci Med Sci. 1999 Jan;54(1):M38-43
10026661
J Nutr Health Aging. 2005 Sep-Oct;9(5):347-51
16222401
Endocr Rev. 1986 Nov;7(4):434-48
3536463
Osteoporos Int. 2003 Jul;14(7):570-6
12844211
Phys Ther. 2000 Sep;80(9):896-903
10960937
N Engl J Med. 1995 Mar 2;332(9):556-61
7838189
Aging Clin Exp Res. 2005 Apr;17(2):133-42
15977462
Age Ageing. 1997 May;26(3):189-93
9223714
Arch Phys Med Rehabil. 1999 Jan;80(1):54-8
9915372
Endocrinology. 2003 Dec;144(12):5138-44
12959989
J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):64-8
9886454
J Am Geriatr Soc. 1991 Feb;39(2):142-8
1991946
Osteoporos Int. 2006;17(9):1318-28
16788853
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):497-501
15225827
Calcif Tissue Int. 1999 Oct;65(4):295-306
10485982
J Bone Miner Res. 2007 Feb;22(2):203-10
17059370
Clin Sci (Lond). 1979 Feb;56(2):157-61
477197
J Musculoskelet Neuronal Interact. 2005 Jun;5(2):127-34
15951628
Osteoporos Int. 2010 Jul;21(7):1237-45
19771489
BMJ. 2008 Jan 19;336(7636):124-6
18202065
Curr Osteoporos Rep. 2008 Jun;6(2):57-61
18778564
J Rheumatol Suppl. 2005 Sep;76:26-32
16142848
N Engl J Med. 1992 Feb 6;326(6):357-62
1729617
Aging (Milano). 2000 Dec;12(6):455-60
11211956
Eur J Appl Physiol Occup Physiol. 1984;52(3):310-4
6539684
Osteoporos Int. 2005 Mar;16(3):332-8
15241585
J Am Geriatr Soc. 2004 Feb;52(2):230-6
14728632
Osteoporos Int. 2005 Dec;16(12):1683-90
15933802
J Bone Miner Res. 2000 Jun;15(6):1113-8
10841179
Nephron. 1976;16(1):31-41
1244564
Am J Public Health. 1994 Apr;84(4):565-70
8154557
Arch Intern Med. 2007 Jan 22;167(2):133-9
17242313
Age Ageing. 1977 Nov;6(4):201-10
596307
J Clin Endocrinol Metab. 2007 Jan;92(1):51-8
17032712
Osteoporos Int. 2005 Feb;16(2):198-203
15221207
J Bone Miner Metab. 2008;26(6):531-42
18979152
Calcif Tissue Int. 1999 Oct;65(4):337-40
10485988
Osteoporos Int. 1999;9(2):163-70
10367045
J Gerontol A Biol Sci Med Sci. 1998 Mar;53(2):M112-9
9520917
Calcif Tissue Int. 2008 Feb;82(2):102-7
18239843
Kidney Int. 2007 Jan;71(1):31-8
17091124
JAMA. 2004 Apr 28;291(16):1999-2006
15113819
Osteoporos Int. 2004 Apr;15(4):301-10
14740153
Age Ageing. 2003 May;32(3):315-20
12720619